When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer ...
The final guidance for the 2028 cycle of the Medicare drug price negotiation reflects CMS’s continued effort to balance ...
Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with the Trump administration, President Donald Trump said Tuesday.The announcement, ...
Among the flurry of executive orders (EOs) issued by President Trump as his first hundred days in office drew to a close are two taking aim at the high cost of prescription drugs. For many ideas in ...
Can a generic drug designed to make chemotherapy work better benefit people with autism? President Trump is touting an “amazing” drug — leucovorin — as “an answer to autism,” a broad range of ...
President Donald Trump and the pharmaceutical giant Pfizer announced an agreement Tuesday to lower medication costs for Medicaid patients, advancing Trump’s “Most Favored Nation” pricing effort to ...
Sept 23 (Reuters) - Scholar Rock (SRRK.O), opens new tab said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party ...
The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...
Infection rates from “nightmare” drug-resistant bacteria have skyrocketed in the United States, scientists warned this week. Cases of patients infected with the gnarly bacteria rose an alarming 70% ...
President Trump on Tuesday announced that Pfizer had agreed to sell its products in the U.S. at “Most Favored Nation” pricing, one day after the administration required companies to respond to his ...
President Donald Trump on Tuesday announced measures aimed at lowering the cost of prescription drugs in the United States, including an agreement with pharmaceutical giant Pfizer and the creation of ...